Amgen announced that it will collaborate with the National Cancer Institute and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles.
In the U.S., lung cancer is the leading cause of cancer death and the second most common cancer.1 Approximately 25-30 percent of non-small cell lung cancers, the most common form of lung cancer, are squamous cell carcinomas. However, there are limited treatment options available for squamous cell carcinomas and development of treatments has been further complicated by the number of potential genetic mutations associated with this form of cancer. Research has demonstrated that squamous cell lung cancer has more than double the genetic mutations compared to other forms of cancer.
Lung-MAP is a biomarker-driven, multi-drug, multi-arm Phase 2/3 registration clinical trial for patients with squamous cell lung cancer. The trial will evaluate five investigational compounds intended to treat squamous cell lung cancer and use genomic sequencing to assign enrolled patients to the treatment arms most likely to provide benefit. Patients will then be randomized into one of five sub-studies where they will receive either standard of care (docetaxel or erlotinib) or biomarker-driven targeted therapy with an investigational agent. Each of these sub-studies will be independently powered for overall survival (OS) with an interim analysis for progression-free survival (PFS) to determine whether to proceed from Phase 2 into Phase 3.
Approximately 500 to 1,000 patients will be screened each year for more than 200 cancer-related genes, and the screenings will inform trial arm selection. Five investigational drugs have been selected for inclusion in the initial trial, including Amgen's rilotumumab, an investigational fully human monoclonal antibody designed to inhibit cancer cell growth and migration.
"Amgen has been at the forefront of biomarker research in an effort to help the medical community understand the different mechanisms of cancer progression and ensure that patients receive treatments that will provide the greatest benefit," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This latest collaboration can significantly speed our understanding of targeted approaches for this complex and underserved form of lung cancer, while demonstrating how genomic testing can drive the evolution of clinical trial design. It may ultimately tell us more about how best to match patients to the right treatments."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- M60-UCD1: Tiny Galaxy, Supermassive Black Hole
- Phase-Change Materials Set New Speed Limit For Silicon
- Life After The 125 GeV Higgs: What Is Left Of Two-Higgs Doublet Models
- Ig Nobel Prizes 2014: From Jesus On Toast To Baby Feces In Sausages
- Longer Telomeres And Genetic Determinant For Melanoma Risk
- Watching Neurons Learn: Learning New Ideas Is More Difficult
- Witness The Singularity AI Nanotech Co-Evolutionary Merger
- "Please re-read the first paragraph. It's missing an ending......"
- "If being very restrained brings you to write stuff as AFAIK he has never talked about the gaps..."
- "Hi Mephisto,we do have a similar problem to the one you mention in high-energy physics - when we..."
- "Concerning his political opinions, Lubos is a deluded annoying crank, but credit has to be given..."
- "Right on, and I have written articles on that issue in the past - by preventing uptake in wealthy..."
- Using plants to produce enzyme may provide treatment for high blood pressure in lungs
- Lithium-sulfur batteries may mean a commercial reality with a bigger energy punch
- Small weight gain can raise blood pressure in healthy adults
- Environmentalists score a win, get government to control plastic bags
- Melanoma risk found to have genetic determinant